I may have said this before....but I bought Sarepta when it was in the $teens and then it jumped to $35 ...a few weeks later it dropped all the way to something like $8 due to a negative response by FDA on their NDA. My coworker and I each had shares and we concluded that the science seemed solid and decided to hold even though the company really only had one indication at the time. Fast forward and it is now at $150/sh and has several indications coming to fruition. I have the same struggle with IPIX...I believe the science is solid (on many fronts with B, P and K), but the SP is not consistent with that thinking.....yet. Sarepta did not have a non-binding term sheet signed and there was no talk of partnering at that time, but there was a lot of bashing going on similar to what is happening with IPIX. I could be completely wrong this time around, but I suspect the BPs see the science as the key issue here and want to get it in their quiver. All IMHO.